Alpha helical mimics, their uses and methods for their production
Disclosed are short chain peptides that are constrained to adopt an alpha helical conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides. Also disclosed is the use of these peptides for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. The peptides find use in mimicking naturally occurring peptides or proteins or in preparing new materials.
1. A compound having a plurality of alpha helical cyclic pentapeptide sequences, which is represented by formula (IV):
wherein each Xaa is independently selected from any amino acid residue;
R 1 is selected from H, an N-terminal capping group, a peptide of 1 to 5 amino acid residues optionally capped by an N-terminal capping group, a non-peptidic group or a group that mimics an amino acid side chain;
R 2 is selected from H, a C-terminal capping group, a peptide of 1 to 5 amino acids optionally capped by a C-terminal capping group, a group that mimics an amino acid side chain or a group that activates the terminal carboxylic acid carbonyl group to nucleophilic substitution;
each R9 and R0 are independently selected from H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 10 cylcoalkyl, C 5 -C 10 cycloalkenyl, —OH, —OC 1 -C 10 alkyl, —NH 2 , —NH(C 1 -C 10 alkyl), —N(C 1 -C 10 alkyl) 2 , C 6 -C 10 aryl, C 3 -C 10 heterocyclyl, C 5 -C 10 heteroaryl and halo;
L is selected from —NH—C(O)—, —C(O)—NH—, —S—S—, —CH(OH)CH 2 —, CH 2 CH(OH)—, —CH═CH—, —CH 2 —CH 2 —, —NH—CH 2 — —CH 2 —NH—, —CH 2 —S—, —S—CH 2 —, —C(O)—CH 2 —, —CH 2 —C(O)—, —S(O) t —NH—, —NH—S(O) t —, CH 2 —P(═O)(OH)— and —P(═O)(OH)—CH 2 —;
m is 4,
n is 1,
t is 0, 1 or 2,
and
p is an integer from 2 to 4.
2. A compound according to claim 1 , wherein an individual pentapeptide sequence is a macrocycle formed by consecutively linking at least 18 to 22 atoms, wherein the first and last atoms are bonded to one another to form a ring.
3. A compound according to claim 2 , wherein the macrocycle is formed from 19 to 21 atoms.
4. A compound according to claim 2 , wherein the macrocycle is formed from 20 atoms.
5. A compound according to claim 1 , wherein the amino-terminal and carboxy-terminal residues of an individual pentapeptide sequence are Lys and Asp, respectively.
6. A compound according to claim 1 , wherein the amino acid side chains of the amino-terminal and carboxy-terminal residues of an individual pentapeptide sequence are covalently linked to one another by a lactam bridge between a side chain amino group and a side chain carboxylic acid group.
7. A compound according to claim 1 , wherein the amino acid residues in the sequence of the peptide are selected from D- or L-α-amino acids.
8. A compound according to claim 1 , wherein the amino acid residues in the sequence of the peptide are selected from L-α-amino acids.
9. A compound according to claim 1 , wherein an individual Xaa is selected from residues that are favorable to helix formation, wherein the residues are selected from alanine, arginine, lysine, methionine, leucine, glutamic acid, glutamine, cysteine, isoleucine, phenylalanine, tyrosine, tryptophan, histidine and aspartic acid.
10. A compound according to claim 1 , which comprises two consecutive alpha helical cyclic pentapeptides spaced from a third alpha helical cyclic pentapeptide by about 1, 2, 5, 8 or 9 natural or unnatural helix-forming amino acid residues.
11. A compound according to claim 1 , which comprises three consecutive alpha helical cyclic pentapeptides spaced from a fourth alpha helical cyclic pentapeptide by about 0, 3, 4, 6 or 7 natural or unnatural helix-forming amino acid residues.
12. A compound according to claim 1 , which comprises three consecutive alpha helical cyclic pentapeptides spaced from a fourth alpha helical cyclic pentapeptide by about 1, 2, 5, 6 or 9 natural or unnatural helix-forming amino acid residues.
13. A compound according to claim 1 , wherein individual pentapeptide sequences are different.
14. A compound according to claim 1 , wherein individual pentapeptide sequences in the peptide are the same.
15. A compound, selected from:
[SEQ ID NO: 46]
cyclo(1-5, 6-10)-Ac-[KARADKARAD]-NH 2 ;
and
[SEQ ID NO: 47].
cyclo(1-5, 6-10, 11-15)-Ac-[KARADKARADKARAD]-NH 2
16. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or adjuvant.